Literature DB >> 23565620

What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.

F Ahmed1.   

Abstract

Summary.  Directly acting antiviral (DAA) agents are currently revolutionizing the treatment of chronic hepatitis C infection. The first generation of these agents have significant limitations including cost issues that are of particular concern in the developing world and a lack of efficacy in genotype 3 patients. Both of these concerns are of particular relevance in Pakistan.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23565620     DOI： 10.1111/j.1365-2893.2012.01613.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN： 1352-0504            Impact factor:   3.728


  2 in total

Review 1.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.

Authors:  Antonio Rivero-Juarez; Luis F López-Cortés; Angela Camacho; Almudena Torres-Cornejo; Ana Gordon; Rosa Ruiz-Valderas; Julian Torre-Cisneros; Juan A Pineda; Pompeyo Viciana; Antonio Rivero
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.